{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:09Z","timestamp":1707524409124},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,12]]},"DOI":"10.7759\/cureus.20364","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T20:59:50Z","timestamp":1639342790000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Follow-Up of a Severe Eosinophilic Asthmatic Patient With Comorbid Nasal Polyposis Hospitalized for SARS-CoV-2 Infection While Receiving Benralizumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Annamaria","family":"Ambrosino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30167-3","article-title":"Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?","volume":"8","author":"Halpin DM","year":"2020","unstructured":"Halpin DM, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respir Med. 2020, 8:436-8. 10.1016\/S2213-2600(20)30167-3","journal-title":"Lancet Respir Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.53854\/liim-2903-4","article-title":"A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy","volume":"29","author":"Koritala T","year":"2021","unstructured":"Koritala T, Hussain A, Pleshkova Y, et al.. A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy. Infez Med. 2021, 29:3. 10.53854\/liim-2903-4","journal-title":"Infez Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004879","article-title":"Outcomes of patients with coronavirus disease 2019 receiving organ support therapies: the International Viral Infection and Respiratory Illness Universal Study Registry","volume":"49","author":"Domecq JP","year":"2021","unstructured":"Domecq JP, Lal A, Sheldrick CR, et al.. Outcomes of patients with coronavirus disease 2019 receiving organ support therapies: the International Viral Infection and Respiratory Illness Universal Study Registry. Crit Care Med. 2021, 49:437-48. 10.1097\/CCM.0000000000004879","journal-title":"Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04474-2020","article-title":"Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study","volume":"58","author":"Beltramo G","year":"2021","unstructured":"Beltramo G, Cottenet J, Mariet AS, et al.. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. Eur Respir J. 2021, 58:2004474. 10.1183\/13993003.04474-2020","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/all.14537","article-title":"Asthma phenotypes, comorbidities, and disease activity in COVID-19: the need of risk stratification","volume":"76","author":"Carli G","year":"2021","unstructured":"Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Asthma phenotypes, comorbidities, and disease activity in COVID-19: the need of risk stratification. Allergy. 2021, 76:955-6. 10.1111\/all.14537","journal-title":"Allergy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/all.14426","article-title":"Is asthma protective against COVID-19?","volume":"76","author":"Carli G","year":"2021","unstructured":"Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19?. Allergy. 2021, 76:866-8. 10.1111\/all.14426","journal-title":"Allergy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang X","year":"2020","unstructured":"Yang X, Yu Y, Xu J, et al.. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020, 8:475-81. 10.1016\/S2213-2600(20)30079-5","journal-title":"Lancet Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/all.14407","article-title":"Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement","volume":"75","author":"Vultaggio A","year":"2020","unstructured":"Vultaggio A, Agache I, Akdis CA, et al.. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy. 2020, 75:2764-74. 10.1111\/all.14407","journal-title":"Allergy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100126","article-title":"COVID-19, asthma, and biological therapies: what we need to know","volume":"13","author":"Morais-Almeida M","year":"2020","unstructured":"Morais-Almeida M, Aguiar R, Martin B, et al.. COVID-19, asthma, and biological therapies: what we need to know. World Allergy Organ J. 2020, 13:100126. 10.1016\/j.waojou.2020.100126","journal-title":"World Allergy Organ J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald JM","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al.. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016, 388:2128-41. 10.1016\/S0140-6736(16)31322-8","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107309","article-title":"A review on the effect of COVID-19 in type 2 asthma and its management","volume":"91","author":"Ghosh S","year":"2021","unstructured":"Ghosh S, Das S, Mondal R, et al.. A review on the effect of COVID-19 in type 2 asthma and its management. Int Immunopharmacol. 2021, 91:107309. 10.1016\/j.intimp.2020.107309","journal-title":"Int Immunopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14047","article-title":"Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia","volume":"75","author":"Cazzaniga M","year":"2021","unstructured":"Cazzaniga M, Fumagalli LA, D'angelo L, et al.. Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia. Int J Clin Pract. 2021, 75:e14047. 10.1111\/ijcp.14047","journal-title":"Int J Clin Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020305","article-title":"The prognostic value of eosinophil recovery in COVID-19: a multicentre, retrospective cohort study on patients hospitalised in Spanish hospitals","volume":"10","author":"Mateos Gonz\u00e1lez M","year":"2021","unstructured":"Mateos Gonz\u00e1lez M, Sierra Gonzalo E, Casado Lopez I, et al.. The prognostic value of eosinophil recovery in COVID-19: a multicentre, retrospective cohort study on patients hospitalised in Spanish hospitals. J Clin Med. 2021, 10:305. 10.3390\/jcm10020305","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106470","article-title":"Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients","volume":"184","author":"Maniscalco M","year":"2021","unstructured":"Maniscalco M, Fuschillo S, Ambrosino P, Martucci M, Papa A, Matera MG, Cazzola M. Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients. Respir Med. 2021, 184:106470. 10.1016\/j.rmed.2021.106470","journal-title":"Respir Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002660","article-title":"Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report (Epub ahead of print)","author":"Kroes JA","year":"2021","unstructured":"Kroes JA, Zielhuis SW, Bethlehem C, Ten Brinke A, Van Roon EN. Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report (Epub ahead of print). Eur J Hosp Pharm. 2021, 10.1136\/ejhpharm-2020-002660","journal-title":"Eur J Hosp Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74295-long-term-follow-up-of-a-severe-eosinophilic-asthmatic-patient-with-comorbid-nasal-polyposis-hospitalized-for-sars-cov-2-infection-while-receiving-benralizumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:39Z","timestamp":1707507219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74295-long-term-follow-up-of-a-severe-eosinophilic-asthmatic-patient-with-comorbid-nasal-polyposis-hospitalized-for-sars-cov-2-infection-while-receiving-benralizumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.20364","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,12]]}}}